SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., ...

Following the live call, a replay will be available in the Investor Relations section of the Company’s website at www.viemed.com. ABOUT VIEMED HEALTHCARE, INC.

We made significant progress advancing Longeveron’s founding mission - developing cutting-edge cellular therapy research to impact patients’ lives for the better by addressing unmet medical needs. We ...

Mesmerize, an MJH Life Sciences ® brand and a leader in patient education at the point of care, is proud to announce that it has been named to the prestigious 2025 Pharmacy500, an annual award ...

This announcement comes as Abivax continues to execute against critical 2025 operational milestones, including the ongoing Phase 3 ABTECT clinical program. The Company confirmed that it remains on ...

Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. (“Digicann” or the ...

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy ...

Introduction to Nerve Freedom! Nerve Pain often referred to as neuropathy — is one of the most frustrating and debilitating ...

Sylvie Grégoire, Chair of Abivax Board of Directors, commented: “We are delighted to welcome Dominik to the Board at such a pivotal moment for Abivax. His extensive background in global medical ...

We are very excited to add Gary to our Board of Directors,” stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. “He brings a strong medtech industry background with a proven ...

First quarter 2025 GAAP net income attributable to Intuitive was $698 million, or $1.92 per diluted share, compared with $545 million, or $1.51 per diluted share, in the first quarter of 2024.

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...